proven to be a valuable factor in combination therapy regardless of PD-L1 expressionvarious cutoff levels for defining TMB leveldifferent platforms were used for TMB estimationdifferent samples were tested for TMB with high rejection rate related to tumor samples. The gene discussed is CD274; the disease is neoplasm.